DCLK1 and neoplasm: The addition of DCLK1 inhibitor DCLK1-IN-1 to the third-generation EGFR-TKI inhibitor Osimertinib resistant PDO downregulates the Wnt/β-catenin signaling pathway, restores tumor sensitivity to Osimertinib [58].